<DOC>
	<DOCNO>NCT00686270</DOCNO>
	<brief_summary>This study examine long term safety apricitabine HIV-1 infected patient study AVX-301 AVX-302 . Eligible patient either ( ) complete study AVX-301 AVX-302 ; ( b ) meet criteria virological failure/lack response , consequently wish withdraw early study AVX-301 AVX-302 .</brief_summary>
	<brief_title>A Long Term Safety Study Apricitabine HIV-infected Patients</brief_title>
	<detailed_description>The clinical study AVX-301 study efficacy safety 800mg 1200mg BID ATC combination optimize background patient HIV-1 infect fail treatment emtricitabine lamivudine confirm M184V/I mutation . Patients achieve least 0.5 log10 copies/mL decrease plasma HIV RNA Week 16 , experience &gt; 1.0 log10 copies/mL increase ( confirmed two separate occasion least one week apart ) plasma HIV RNA nadir Week 16 , eligible screen entry study . In addition , patient complete study AVX-301 also eligible screening . The clinical study AVX-302 similar study efficacy safety single dose ATC ( determine AVX-301 ) . Patients AVX-302 experience virologic failure lack virologic response similarly eligible screen entry study . In addition , patient complete study AVX-302 also eligible screening . This phase 3 , open-label , multi-center study 96 week duration . Patients receive 96 week open-label ATC , initially dose 1200mg orally BID . Following selection optimum ATC dose protocol AVX-301 termination one two ATC dos ( 800mg 1200mg orally BID ) protocol AVX-301 , patient protocol transfer optimum dose , require . The total number patient expect enrolled study AVX-301 AVX-302 approximately 1866 total.Patients receive ATC orally combination exist ART . Background antiretroviral therapy ( ART ) may revise time study discretion investigator must include lamivudine , emtricitabine , zalcitabine deoxycytidine analogue NRTI . The study examine safety tolerability long term treatment apricitabine combination ART .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Patients complete study AVX301 AVX302 : Patients meet criterion virologic failure/lack response study AVX301 AVX302 18 year age , old Male , nonpregnant , nonbreastfeeding female patient , agree comply applicable contraceptive requirement protocol . Prior withdrawal AVX301 AVX302 Current acute chronic hepatitis B virus infection Current treatment hepatitis C virus infection Renal Function adequate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>NRTI resistance</keyword>
	<keyword>M184V mutation</keyword>
	<keyword>reverse transcriptase</keyword>
	<keyword>apricitabine</keyword>
	<keyword>drug resistance</keyword>
	<keyword>safety tolerability</keyword>
	<keyword>therapy failure</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>